Asian Spectator

Times Advertising

Aspire Secures Securities and Asset Management Licences from Hong Kong’s Securities and Futures Commission

Regulatory milestone paves the way for launch of Aspire Yield, enabling businesses to earn attractive returns on idle cash balancesHONG KONG SAR - Media OutReach Newswire - 15 April 2026 - Aspire, th...

BlueBee Establishes Data Center in Mainland China, Expanding G...

RIJSWIJK, Netherlands, October 9,2019/PRNewswire--AsiaNet/ BlueBee, a global bioinformatics solutions provider, has extended data operations to mainland China to serve genomic data processin...

Over half of APAC CIOs believe flexible working is key to retaining and recruiting skilled employees

- 44% of APAC CIOs believe that having a flexible working policy has opened the door to a wider pool of highly skilled individuals. - Almost a third (32%) of APAC CIOs had to hire someone t...

Smart Logistics Solution Provider ProA Empowers PUIG's Omni-Ch...

HANGZHOU, China, Nov. 19, 2021 /PRNewswire-AsiaNet/ -- PUIG and ProA Supply Chain has jointly announced the opening of PUIG's China Distribution Center (CDC) in Hangzhou, China at a launch c...

In celebration of the 75th anniversary of the founding of the People’s Republic of China, Sun Hung Kai Properties’ New Town Plaza 40th anniversary celebration ceremony

Hong Kong's first spectacular pyrotechnic show at a shopping mall 2,024 dazzling pyrotechnics light up Sha Tin's night skyA day of exciting free activities, 300 shopping discounts and mega e...

JA Solar Supplies 134MW of High-efficiency PERC Double-glass M...

BEIJING, Nov. 21, 2019 /PRNewswire-AsiaNet/ -- JA Solar, a world-leading manufacturer of high-performance photovoltaic products, announced that it supplied all high-efficiency PERC double-gl...

Alltronics Launches the Second Generation Portable Photocatalyst Deodoriser at 2018 Hong Kong Electronics Fair

Alltronics launches the second generation portable photocatalyst deodoriser at 2018 Hong Kong Electronics FairMr. Lam Yin Kee, Chairman of Alltronics and Ms. Ivy Lam, Investor Relationship M...

Results of the Post-pandemic Survey on Perceived Family Xingfu

Nearly Sixty Percent of Respondents Reported a High Family Xingfu Score Improve Family Communication, Express Affection and Prioritise Quality Time For Greater Family Health, Happiness ...

Artmarket.com and Artprice announce the forthcoming publicatio...

PARIS, Oct 6, 2020 /PRNewswire-AsiaNet / -- Over the past twenty years the exchange of Contemporary art works has developed into a dynamic global market. In its upcoming publication, Artpric...

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

SYDNEY, Apr 8, 2020 - (ACN Newswire) - Asia-Pacific's largest specialist biotech CRO Novotech said the top 10 biotech sites in Australia were open for clinical trial activity with many sites modifying their practices to ensure continuity of operations.

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

View and Download the COVID-19 Australia Data Bulletin here. https://novotech-cro.com/covid-19-notice

The data is part of a new series prepared for Novotech clients detailing the current status of trials in the Asia-Pacific during the global COVID-19 crisis.

Novotech CEO Dr John Moller said the Bulletin series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for Novotech and its clients during this time.

"While the situation is always evolving, Australia appears to be managing the crisis well. Our sites have changed how they manage trials in line with Australian Government health guidelines and most are still able to deliver the clinical trial services we need for our clients," said Dr Moller. "Study delays caused by COVID-19 can be rapidly addressed by activating new sites in Australia and Asia."

Australia has attractive start-up times, world leading investigators and research teams, and valuable rebates of up to 43.5% on clinical trial spend.

About Novotech

Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotech companies.

Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit http://novotech-cro.com.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media ContactSusan Fitzpatrick-Napiercommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Krisis ojol: Promo selalu mencekik pengemudi, jam-jam padat malah bikin rugi

● Masyarakat makin sering mengeluhkan langkanya ojol di waktu-waktu tertentu.● Padahal seharusnya upah yang didapat para ojol meningkat jika melihat meroketnya tarif yang dibebankan kepada...

Benarkah sering ejakulasi bisa kurangi risiko kanker prostat? Jawabannya tidak sesederhana itu

Kanker prostat menempati urutan kedua global sebagai jenis kanker paling banyak didiagnosis pada laki-laki, setelah kanker paru-paru. Di Inggris, kanker prostat merupakan kanker yang paling umum diala...

Jejak pengetahuan astronomi Nusantara sejak lebih dari 1000 tahun lalu: Dari candi hingga prasasti kuno

● Astronomi Indonesia telah berkembang sejak abad ke-7 dan ke-8 Masehi, jauh sebelum Observatorium Bosscha berdiri pada 1920.● Pendekatan astro-arkeologi mengungkap bahwa orientasi candi e...